JP2012126750A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012126750A5 JP2012126750A5 JP2012081700A JP2012081700A JP2012126750A5 JP 2012126750 A5 JP2012126750 A5 JP 2012126750A5 JP 2012081700 A JP2012081700 A JP 2012081700A JP 2012081700 A JP2012081700 A JP 2012081700A JP 2012126750 A5 JP2012126750 A5 JP 2012126750A5
- Authority
- JP
- Japan
- Prior art keywords
- molecule
- vwf
- fviii
- proteinaceous
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010047303 von Willebrand Factor Proteins 0.000 claims 135
- 102100036537 von Willebrand factor Human genes 0.000 claims 131
- 229960001134 von willebrand factor Drugs 0.000 claims 131
- 108010054218 Factor VIII Proteins 0.000 claims 94
- 102000001690 Factor VIII Human genes 0.000 claims 94
- 229960000301 factor viii Drugs 0.000 claims 94
- 239000002202 Polyethylene glycol Substances 0.000 claims 31
- 238000001727 in vivo Methods 0.000 claims 31
- 229920001223 polyethylene glycol Polymers 0.000 claims 31
- 238000000034 method Methods 0.000 claims 29
- 239000012634 fragment Substances 0.000 claims 28
- 239000002243 precursor Substances 0.000 claims 28
- 230000004071 biological effect Effects 0.000 claims 22
- 239000003153 chemical reaction reagent Substances 0.000 claims 21
- 241000124008 Mammalia Species 0.000 claims 16
- 229920000642 polymer Polymers 0.000 claims 14
- 239000000539 dimer Substances 0.000 claims 10
- 150000001720 carbohydrates Chemical class 0.000 claims 8
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 8
- 239000008280 blood Substances 0.000 claims 7
- 210000004369 blood Anatomy 0.000 claims 7
- 230000007849 functional defect Effects 0.000 claims 7
- 208000031169 hemorrhagic disease Diseases 0.000 claims 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 7
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 6
- 230000007812 deficiency Effects 0.000 claims 6
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 6
- 102000008186 Collagen Human genes 0.000 claims 5
- 108010035532 Collagen Proteins 0.000 claims 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 5
- 229920001436 collagen Polymers 0.000 claims 5
- 239000002253 acid Substances 0.000 claims 4
- 238000003556 assay Methods 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- -1 poly (alkylene glycol Chemical compound 0.000 claims 4
- 238000000159 protein binding assay Methods 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 4
- 229920002674 hyaluronan Polymers 0.000 claims 3
- 229960003160 hyaluronic acid Drugs 0.000 claims 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 229920001389 Poly(hydroxyalkylmethacrylamide) Polymers 0.000 claims 2
- 150000001336 alkenes Chemical class 0.000 claims 2
- 229940061720 alpha hydroxy acid Drugs 0.000 claims 2
- 150000001280 alpha hydroxy acids Chemical class 0.000 claims 2
- 229920001577 copolymer Polymers 0.000 claims 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 2
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 claims 2
- 229920000765 poly(2-oxazolines) Polymers 0.000 claims 2
- 229920001390 poly(hydroxyalkylmethacrylate) Polymers 0.000 claims 2
- 229920001583 poly(oxyethylated polyols) Polymers 0.000 claims 2
- 229920001451 polypropylene glycol Polymers 0.000 claims 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 2
- 239000000047 product Substances 0.000 claims 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims 2
- 229920002554 vinyl polymer Polymers 0.000 claims 2
- ZJIFDEVVTPEXDL-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) hydrogen carbonate Chemical compound OC(=O)ON1C(=O)CCC1=O ZJIFDEVVTPEXDL-UHFFFAOYSA-N 0.000 claims 1
- XLPJNCYCZORXHG-UHFFFAOYSA-N 1-morpholin-4-ylprop-2-en-1-one Chemical compound C=CC(=O)N1CCOCC1 XLPJNCYCZORXHG-UHFFFAOYSA-N 0.000 claims 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 1
- 229920001734 PEG propionaldehyde Polymers 0.000 claims 1
- 239000002262 Schiff base Substances 0.000 claims 1
- 150000004753 Schiff bases Chemical class 0.000 claims 1
- 125000003172 aldehyde group Chemical group 0.000 claims 1
- 150000001299 aldehydes Chemical class 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- ACBQROXDOHKANW-UHFFFAOYSA-N bis(4-nitrophenyl) carbonate Chemical compound C1=CC([N+](=O)[O-])=CC=C1OC(=O)OC1=CC=C([N+]([O-])=O)C=C1 ACBQROXDOHKANW-UHFFFAOYSA-N 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 239000003638 chemical reducing agent Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 238000004132 cross linking Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims 1
- 230000023597 hemostasis Effects 0.000 claims 1
- 229920000669 heparin Polymers 0.000 claims 1
- 229960002897 heparin Drugs 0.000 claims 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims 1
- 239000000413 hydrolysate Substances 0.000 claims 1
- 230000007062 hydrolysis Effects 0.000 claims 1
- 238000006460 hydrolysis reaction Methods 0.000 claims 1
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000007800 oxidant agent Substances 0.000 claims 1
- 230000001590 oxidative effect Effects 0.000 claims 1
- 230000010412 perfusion Effects 0.000 claims 1
- 230000002572 peristaltic effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000006268 reductive amination reaction Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63924404P | 2004-12-27 | 2004-12-27 | |
| US60/639,244 | 2004-12-27 | ||
| US66837805P | 2005-04-04 | 2005-04-04 | |
| US60/668,378 | 2005-04-04 | ||
| US67190105P | 2005-04-15 | 2005-04-15 | |
| US60/671,901 | 2005-04-15 | ||
| US68508605P | 2005-05-26 | 2005-05-26 | |
| US60/685,086 | 2005-05-26 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007548552A Division JP5022231B2 (ja) | 2004-12-27 | 2005-12-23 | ポリマー−フォンビルブラント因子結合体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012126750A JP2012126750A (ja) | 2012-07-05 |
| JP2012126750A5 true JP2012126750A5 (cg-RX-API-DMAC7.html) | 2013-05-30 |
| JP5715983B2 JP5715983B2 (ja) | 2015-05-13 |
Family
ID=36540284
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007548552A Expired - Lifetime JP5022231B2 (ja) | 2004-12-27 | 2005-12-23 | ポリマー−フォンビルブラント因子結合体 |
| JP2012081700A Expired - Lifetime JP5715983B2 (ja) | 2004-12-27 | 2012-03-30 | ポリマー−フォンビルブラント因子結合体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007548552A Expired - Lifetime JP5022231B2 (ja) | 2004-12-27 | 2005-12-23 | ポリマー−フォンビルブラント因子結合体 |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US7884075B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1835938B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP5022231B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20070092754A (cg-RX-API-DMAC7.html) |
| CN (1) | CN101163506B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2005322067B8 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0519562A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2591852A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK1835938T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2434035T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL183634A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2007007877A (cg-RX-API-DMAC7.html) |
| PL (1) | PL1835938T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT1835938E (cg-RX-API-DMAC7.html) |
| WO (1) | WO2006071801A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6263355A (ja) * | 1985-09-13 | 1987-03-20 | Hitachi Ltd | バツテリバツクアツプｒａｍのチエツク方法 |
| DK1835938T3 (da) * | 2004-12-27 | 2013-11-04 | Baxter Int | Polymer-von Willebrand-faktor-konjugater |
| JP2009532351A (ja) | 2006-03-31 | 2009-09-10 | バクスター・インターナショナル・インコーポレイテッド | ペグ化第ｖｉｉｉ因子 |
| US7982010B2 (en) | 2006-03-31 | 2011-07-19 | Baxter International Inc. | Factor VIII polymer conjugates |
| US7985839B2 (en) | 2006-03-31 | 2011-07-26 | Baxter International Inc. | Factor VIII polymer conjugates |
| US7645860B2 (en) | 2006-03-31 | 2010-01-12 | Baxter Healthcare S.A. | Factor VIII polymer conjugates |
| ES2531934T3 (es) | 2006-09-01 | 2015-03-20 | Novo Nordisk Health Care Ag | Glicoproteínas modificadas |
| ES2521490T3 (es) * | 2006-12-15 | 2014-11-12 | Baxter International Inc. | Conjugado de factor VIIa - ácido (poli)siálico con una vida media in vivo prolongada. |
| MX2009007145A (es) * | 2006-12-27 | 2009-08-27 | Nektar Therapeutics Al Corp | Conjugados de polimero con factor viii y factor de von willebrand que tienen una ligadura liberable. |
| KR101156263B1 (ko) * | 2007-05-18 | 2012-06-13 | 박스터 헬쓰케어 에스.에이. | 폰 빌리브란트 인자 프로펩티드로부터 성숙한 폰 빌리브란트 인자를 제조하는 방법 |
| JP2010529155A (ja) * | 2007-06-13 | 2010-08-26 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 出血性疾患の治療及び予防的処置における血管外投与のためのｖｗｆ安定化ｆｖｉｉｉ製剤及びｆｖｉｉｉなしのｖｗｆ製剤の使用 |
| US7700551B2 (en) * | 2007-06-26 | 2010-04-20 | Baxter International Inc. | Hydrolysable polymeric FMOC-linker |
| WO2009062100A1 (en) * | 2007-11-09 | 2009-05-14 | Baxter International Inc. | Modified recombinant factor viii and von willebrand factor and methods of use |
| KR20160012252A (ko) | 2007-12-27 | 2016-02-02 | 백스터 인터내셔널 인코포레이티드 | 생리학적으로 수용가능한 중합체 분자를 특이적으로 검출하기 위한 방법 및 조성물 |
| BRPI0821597A2 (pt) * | 2007-12-27 | 2015-06-16 | Baxter Int | Métodos para quantificar a quantidade de proteína derivada de plasma e proteína recombinante em uma amostra e para diferenciar proteína derivada de plasma e proteína recombinante em uma amostra, e, kit. |
| US11197916B2 (en) | 2007-12-28 | 2021-12-14 | Takeda Pharmaceutical Company Limited | Lyophilized recombinant VWF formulations |
| AR069989A1 (es) | 2007-12-28 | 2010-03-03 | Baxter Int | Formulaciones de vwf recombinantes |
| EP2235188A2 (en) | 2007-12-31 | 2010-10-06 | Baxter International Inc. | Transgenic non-human animals expressing human blood clotting factors |
| KR20110028444A (ko) * | 2008-05-06 | 2011-03-18 | 옥타파마 아게 | 헤파린 결합 단백질 및 헤파린―히드록시알킬 전분 접합체를 포함하는 복합체 |
| DK2865760T3 (en) * | 2008-06-24 | 2018-01-15 | Csl Behring Gmbh | Factor VIII, Von Willebrand Factor or complexes thereof with extended in vivo half-life |
| NZ590358A (en) * | 2008-07-23 | 2012-04-27 | Hanmi Holdings Co Ltd | A polypeptide complex comprising non-peptidyl polymer having three functional ends |
| US8575102B2 (en) * | 2008-08-01 | 2013-11-05 | Nektar Therapeutics | Conjugates having a releasable linkage |
| JP5785872B2 (ja) | 2008-10-17 | 2015-09-30 | バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ | 低度の水溶性ポリマーを含む改変血液因子 |
| US8586710B2 (en) * | 2008-10-20 | 2013-11-19 | Usv, Ltd. | Process for gram scale production of PEG-r-metHuG-CSF |
| EP2350658A2 (en) * | 2008-10-21 | 2011-08-03 | Baxter International Inc. | Methods for determining active ingredients in pro-drug peg protein conjugates with releasable peg reagents (in vitro de-pegylation) |
| KR101772674B1 (ko) * | 2008-10-21 | 2017-09-01 | 박스알타 인코퍼레이티드 | 동결건조된 재조합 ｖｗｆ 제제 |
| DK2356467T3 (da) * | 2008-12-11 | 2013-10-14 | Baxter Int | Påvisning af fysiologisk acceptable polymermolekyler under anvendelse af nær-infrarød spektroskopi |
| NZ597600A (en) | 2009-07-27 | 2014-05-30 | Lipoxen Technologies Ltd | Glycopolysialylation of non-blood coagulation proteins |
| US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| JP5908401B2 (ja) | 2009-07-27 | 2016-04-26 | バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ | 血液凝固タンパク質複合体 |
| US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| RU2744370C2 (ru) | 2009-07-27 | 2021-03-05 | Баксалта Инкорпорейтед | Конъюгаты белков свертывания крови |
| EP2462231A2 (en) * | 2009-08-04 | 2012-06-13 | Baxter International Inc | Transgenic mouse lacking endogenous fviii and vwf - a model of hemophilia a |
| CN106008697B (zh) | 2009-08-20 | 2020-08-04 | 百深公司 | 纯化vwf以增加非-脂质包封的病毒的去除 |
| JP2013502458A (ja) | 2009-08-24 | 2013-01-24 | アムニクス オペレーティング インコーポレイテッド | 凝固第ｖｉｉ因子組成物ならびにそれを製造および使用する方法 |
| JP5876416B2 (ja) * | 2009-11-13 | 2016-03-02 | グリフオルス・セラピユーテイクス・インコーポレーテツドＧｒｉｆｏｌｓ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | フォンウィルブランド因子（ｖＷＦ）含有調製品並びにこれに関連する方法、キット及び使用 |
| GB201007357D0 (en) * | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIII |
| KR102269494B1 (ko) | 2010-07-30 | 2021-06-25 | 박스알타 인코퍼레이티드 | 옥심 결합용 친핵성 촉매 |
| KR101309566B1 (ko) * | 2010-12-10 | 2013-09-17 | 포항공과대학교 산학협력단 | 히알루론산-단백질 컨쥬게이트 및 이의 제조 방법 |
| NZ612320A (en) | 2010-12-22 | 2015-06-26 | Baxter Healthcare Sa | Materials and methods for conjugating a water soluble fatty acid derivative to a protein |
| EP2714093A1 (en) | 2011-05-27 | 2014-04-09 | Baxter International Inc. | Therapeutic proteins with increased half-life and methods of preparing same |
| AR086904A1 (es) * | 2011-06-10 | 2014-01-29 | Baxter Int | Tratamiento de trastornos de la coagulacion por medio de la administracion de factor recombinante de von willebrand (vwf) |
| KR102212098B1 (ko) * | 2012-01-12 | 2021-02-03 | 바이오버라티브 테라퓨틱스 인크. | 키메라 인자 viii 폴리펩티드들과 이의 용도 |
| ES2651523T3 (es) | 2012-02-15 | 2018-01-26 | Csl Behring Gmbh | Variantes del Factor de von Willebrand que tienen afinidad de unión al Factor VIII mejorada |
| JP6383666B2 (ja) | 2012-02-15 | 2018-08-29 | バイオベラティブ セラピューティクス インコーポレイテッド | 組換え第ｖｉｉｉ因子タンパク質 |
| MX369862B (es) | 2012-02-15 | 2019-11-25 | Bioverativ Therapeutics Inc | Composiciones del factor viii y metodos para hacerlas y usarlas. |
| AU2013204754C1 (en) | 2012-05-16 | 2018-10-11 | Takeda Pharmaceutical Company Limited | Nucleophilic Catalysts for Oxime Linkage |
| EA201792485A3 (ru) * | 2012-07-11 | 2019-03-29 | Амуникс Оперэйтинг Инк. | Комплекс фактора viii с xten и белком-фактором фон виллебранда, и его применение (варианты) |
| DK2796145T3 (da) * | 2013-04-22 | 2018-01-29 | Csl Ltd | Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro |
| EP3875106A1 (en) * | 2013-08-08 | 2021-09-08 | Bioverativ Therapeutics Inc. | Purification of chimeric fviii molecules |
| TWI667255B (zh) | 2013-08-14 | 2019-08-01 | 美商生物化學醫療公司 | 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途 |
| MY204756A (en) | 2014-01-10 | 2024-09-11 | Bioverativ Therapeutics Inc | Factor viii chimeric proteins and uses thereof |
| EP3158055B1 (en) | 2014-06-13 | 2019-09-11 | CSL Limited | Improved production of recombinant von willebrand factor in a bioreactor |
| JP6676551B2 (ja) | 2014-07-02 | 2020-04-08 | ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト | 改変フォンウィルブランド因子 |
| CN104491917B (zh) * | 2014-12-30 | 2018-01-09 | 广州市拜特凇医药科技有限公司 | 一种含有peg或其衍生物的生物材料 |
| ES2772933T3 (es) | 2015-03-06 | 2020-07-08 | CSL Behring Lengnau AG | Factor de von Willebrand modificado que tiene una semivida mejorada |
| SG10201910896UA (en) | 2015-05-22 | 2020-01-30 | CSL Behring Lengnau AG | Truncated von willebrand factor polypeptides for treating hemophilia |
| US10772936B2 (en) | 2015-05-22 | 2020-09-15 | CSL Behring Lengnau AG | Methods for preparing modified von Willebrand factor |
| JP2015155469A (ja) * | 2015-06-01 | 2015-08-27 | バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ | 第ｆｖｉｉｉ因子ポリマー結合体 |
| IL257231B (en) | 2015-08-03 | 2022-09-01 | Bioverativ Therapeutics Inc | Factor ix fusion proteins and methods of making and using same |
| RU2018128613A (ru) | 2016-01-07 | 2020-02-07 | Цсл Беринг Ленгнау Аг | Мутированный фактор фон виллебранда |
| ES2909573T3 (es) | 2016-01-07 | 2022-05-09 | CSL Behring Lengnau AG | Factor de von Willebrand truncado mutado |
| DK3538134T3 (da) | 2016-11-11 | 2022-02-07 | CSL Behring Lengnau AG | Trunkeret von willebrand-faktor polypeptider til ekstravaskulær administration til behandling eller profylakse af en blodkoagulationsforstyrrelse |
| SG11201903950UA (en) | 2016-11-11 | 2019-05-30 | CSL Behring Lengnau AG | Truncated von willebrand factor polypeptides for treating hemophilia |
| CN110520150A (zh) | 2016-12-02 | 2019-11-29 | 比奥维拉迪维治疗股份有限公司 | 使用嵌合凝血因子治疗血友病性关节病的方法 |
| US10632176B2 (en) | 2017-07-07 | 2020-04-28 | Baxalta Incorporated | Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF |
| AU2018298232B2 (en) | 2017-07-07 | 2025-04-03 | Takeda Pharmaceutical Company Limited | Treatment of patients with severe von willebrand disease undergoing elective surgery by administration of recombinant VWF |
| SG11202000695RA (en) | 2017-08-23 | 2020-03-30 | Csl Behring Gmbh | Method for virus filtration of von willebrand factor |
| JP2018115170A (ja) * | 2018-03-02 | 2018-07-26 | バクスアルタ ゲーエムベーハー | 第ｆｖｉｉｉ因子ポリマー結合体 |
| EA202092223A1 (ru) | 2018-03-21 | 2021-02-10 | Баксалта Инкорпорейтед | Разделение vwf и пропептида vwf хроматографическими методами |
| LT3793588T (lt) | 2018-05-18 | 2025-06-25 | Bioverativ Therapeutics Inc. | Hemofilijos a gydymo būdai |
| CN113645993A (zh) | 2019-02-01 | 2021-11-12 | 武田药品工业株式会社 | 使用重组VWF(rVWF)进行预防性治疗的方法 |
| JP2022547556A (ja) | 2019-09-11 | 2022-11-14 | 武田薬品工業株式会社 | フォン・ヴィレブランド因子と補体ｃ１ｑの複合体に関連する治療法 |
| CN115335074A (zh) | 2020-02-04 | 2022-11-11 | 武田药品工业株式会社 | 通过施用重组vwf来治疗患有重度冯维勒布兰德病的患者的月经过多 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2004A (en) * | 1841-03-12 | Improvement in the manner of constructing and propelling steam-vessels | ||
| US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4356170A (en) | 1981-05-27 | 1982-10-26 | Canadian Patents & Development Ltd. | Immunogenic polysaccharide-protein conjugates |
| JPS59172425A (ja) * | 1983-03-18 | 1984-09-29 | Nippon Chemiphar Co Ltd | 新規な血液凝固因子誘導体およびその製造法ならびにそれを含有する血液凝固促進剤 |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
| US4970300A (en) | 1985-02-01 | 1990-11-13 | New York University | Modified factor VIII |
| JPS62502589A (ja) | 1985-04-11 | 1987-10-08 | ザ・チヤイルドレンズ・メデイカル・センタ−・コ−ポレ−シヨン | フオン・ビルブラント因子 |
| CA1339946C (en) | 1987-03-31 | 1998-07-07 | Michael J. Griffith | Ultrapurification process for polypeptides |
| US5605884A (en) | 1987-10-29 | 1997-02-25 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Factor VIII formulations in high ionic strength media |
| US4877608A (en) | 1987-11-09 | 1989-10-31 | Rorer Pharmaceutical Corporation | Pharmaceutical plasma protein formulations in low ionic strength media |
| US5122614A (en) * | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| DE4001451A1 (de) | 1990-01-19 | 1991-08-01 | Octapharma Ag | Stabile injizierbare loesungen von faktor viii und faktor ix |
| US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
| DE4111393A1 (de) | 1991-04-09 | 1992-10-15 | Behringwerke Ag | Stabilisierte faktor viii-praeparationen |
| US5846951A (en) | 1991-06-06 | 1998-12-08 | The School Of Pharmacy, University Of London | Pharmaceutical compositions |
| WO1993000357A1 (en) | 1991-06-28 | 1993-01-07 | Rhone-Poulenc Rorer International (Holdings) Inc. | Therapeutic polypeptides based on von willebrand factor |
| US6037452A (en) * | 1992-04-10 | 2000-03-14 | Alpha Therapeutic Corporation | Poly(alkylene oxide)-Factor VIII or Factor IX conjugate |
| EP0627924B1 (en) | 1992-10-02 | 2000-12-27 | Genetics Institute, Inc. | Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer |
| US5298643A (en) * | 1992-12-22 | 1994-03-29 | Enzon, Inc. | Aryl imidate activated polyalkylene oxides |
| AU6029594A (en) * | 1993-01-15 | 1994-08-15 | Enzon, Inc. | Factor viii - polymeric conjugates |
| US5621039A (en) | 1993-06-08 | 1997-04-15 | Hallahan; Terrence W. | Factor IX- polymeric conjugates |
| US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| DE4435485C1 (de) | 1994-10-04 | 1996-03-21 | Immuno Ag | Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor |
| US6127153A (en) | 1995-06-07 | 2000-10-03 | Neose Technologies, Inc. | Method of transferring at least two saccharide units with a polyglycosyltransferase, a polyglycosyltransferase and gene encoding a polyglycosyltransferase |
| SE9503380D0 (sv) * | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
| US6005077A (en) | 1995-11-10 | 1999-12-21 | Immuno Aktiengesellschaft | Use of von willebrand factor and pharmaceutical formulation |
| US6562781B1 (en) * | 1995-11-30 | 2003-05-13 | Hamilton Civic Hospitals Research Development Inc. | Glycosaminoglycan-antithrombin III/heparin cofactor II conjugates |
| US5763401A (en) | 1996-07-12 | 1998-06-09 | Bayer Corporation | Stabilized albumin-free recombinant factor VIII preparation having a low sugar content |
| US6214966B1 (en) | 1996-09-26 | 2001-04-10 | Shearwater Corporation | Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution |
| AT405740B (de) | 1996-12-13 | 1999-11-25 | Immuno Ag | Von willebrand-faktor-derivat sowie ein verfahren zur isolierung von proteinen |
| AT405403B (de) | 1997-02-27 | 1999-08-25 | Immuno Ag | Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie |
| AT405485B (de) | 1997-05-28 | 1999-08-25 | Immuno Ag | Eine das vwf-propeptid enthaltende pharmazeutische präparation |
| AU2855499A (en) | 1998-03-24 | 1999-10-18 | Nof Corporation | Oxirane derivatives and process for producing the same |
| AT407750B (de) | 1999-02-19 | 2001-05-25 | Immuno Ag | Verfahren zur herstellung einer vwf-präparation |
| CN100553678C (zh) | 1999-02-22 | 2009-10-28 | 巴克斯特国际有限公司 | 新的无白蛋白的因子ⅷ制剂 |
| WO2001005434A2 (en) | 1999-07-20 | 2001-01-25 | Amgen Inc. | Hyaluronic acid-protein conjugates |
| SE515295C2 (sv) | 1999-11-23 | 2001-07-09 | Medicarb Ab | Förfarande för framställning av konjugat av en biologiskt aktiv polysackarid och ett fast substrat, samt sådana konjugat |
| AUPR610501A0 (en) | 2001-07-04 | 2001-07-26 | Smart Drug Systems Inc | Treatment of parasitic disease |
| US7265084B2 (en) | 2001-10-10 | 2007-09-04 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
| WO2003040211A2 (en) | 2001-11-07 | 2003-05-15 | Nektar Therapeutics Al, Corporation | Branched polymers and their conjugates |
| EP2572733A1 (en) * | 2003-02-26 | 2013-03-27 | Nektar Therapeutics | Polymer-factor VIII moiety conjugates |
| US20050176108A1 (en) | 2003-03-13 | 2005-08-11 | Young-Min Kim | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
| US20040247624A1 (en) | 2003-06-05 | 2004-12-09 | Unger Evan Charles | Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility |
| JP2007509843A (ja) | 2003-10-07 | 2007-04-19 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 第ＶＩＩ／ＶＩＩａ因子活性を有するハイブリッド分子 |
| WO2005058366A2 (en) | 2003-12-10 | 2005-06-30 | Nektar Therapeutics Al, Corporation | Compositions comprising two different populations of polymer-active agent conjugates |
| DK1835938T3 (da) * | 2004-12-27 | 2013-11-04 | Baxter Int | Polymer-von Willebrand-faktor-konjugater |
-
2005
- 2005-12-23 DK DK05855442.9T patent/DK1835938T3/da active
- 2005-12-23 US US11/317,582 patent/US7884075B2/en active Active
- 2005-12-23 AU AU2005322067A patent/AU2005322067B8/en active Active
- 2005-12-23 BR BRPI0519562-4A patent/BRPI0519562A2/pt not_active IP Right Cessation
- 2005-12-23 WO PCT/US2005/046879 patent/WO2006071801A2/en not_active Ceased
- 2005-12-23 MX MX2007007877A patent/MX2007007877A/es active IP Right Grant
- 2005-12-23 EP EP05855442.9A patent/EP1835938B1/en not_active Expired - Lifetime
- 2005-12-23 PL PL05855442T patent/PL1835938T3/pl unknown
- 2005-12-23 CA CA002591852A patent/CA2591852A1/en not_active Abandoned
- 2005-12-23 CN CN2005800445983A patent/CN101163506B/zh not_active Expired - Lifetime
- 2005-12-23 JP JP2007548552A patent/JP5022231B2/ja not_active Expired - Lifetime
- 2005-12-23 KR KR1020077017261A patent/KR20070092754A/ko not_active Withdrawn
- 2005-12-23 PT PT58554429T patent/PT1835938E/pt unknown
- 2005-12-23 ES ES05855442T patent/ES2434035T3/es not_active Expired - Lifetime
-
2007
- 2007-06-04 IL IL183634A patent/IL183634A/en active IP Right Grant
-
2011
- 2011-01-14 US US13/007,208 patent/US8076463B2/en not_active Expired - Lifetime
- 2011-11-28 US US13/305,334 patent/US8357779B2/en not_active Expired - Lifetime
-
2012
- 2012-03-30 JP JP2012081700A patent/JP5715983B2/ja not_active Expired - Lifetime
- 2012-12-21 US US13/724,831 patent/US8835388B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012126750A5 (cg-RX-API-DMAC7.html) | ||
| JP2008525491A5 (cg-RX-API-DMAC7.html) | ||
| JP6347468B2 (ja) | 組換えフォンウィルブランド因子の投与による凝固疾患の治療 | |
| JP6567577B2 (ja) | Ｔｆｐｉインヒビターおよび使用法 | |
| RU2719562C2 (ru) | Пептидные дендримеры, содержащие фибриноген-связывающие пептиды | |
| JP5870088B2 (ja) | 共役血液凝固第ｖｉｉｉ因子 | |
| JP7071093B2 (ja) | 血液凝固タンパク質複合体 | |
| RU2012106150A (ru) | Вариантные формы уратоксидазы и их применение | |
| MXPA05009169A (es) | Conjugados de polimero-porcion del factor viii. | |
| AU2012268078B2 (en) | Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived Factor-1 | |
| AU2016362606A1 (en) | Factor VIII with extended half-life and reduced ligand-binding properties | |
| JPWO2011149016A1 (ja) | 血栓溶解酵素含有複合体 | |
| JP2017509602A (ja) | ペプチド及びその使用方法 | |
| HK1127300A (en) | Pegylated factor viii |